The landscape of Medicare prescription drug coverage is undergoing a significant shift, driven by the surging popularity of GLP-1 medications. Originally developed for type 2 diabetes, these drugs – including Ozempic and Mounjaro – are increasingly recognized for their effectiveness in weight management and cardiovascular health, leading to a dramatic increase in both usage and spending.
The GLP-1 Wave and Medicare
Currently, Medicare covers GLP-1 drugs for conditions like type 2 diabetes, cardiovascular disease, and sleep apnea. However, coverage for weight loss remains restricted, despite growing clinical evidence supporting their use in obesity treatment.
Usage Trends
Data from CMS reveals a striking increase in GLP-1 utilization within Medicare Part D. Between 2019 and 2024, total GLP-1 claims quadrupled, rising from 4.8 million to 21.8 million. Ozempic experienced an average annual growth rate exceeding 80 percent, with claims jumping from approximately 524,000 to over 10 million. Mounjaro, approved in 2022, saw even faster adoption, reaching 5.1 million claims in 2024 from around 122,000 in 2022.
Older GLP-1 therapies like Victoza and Byetta are gradually being replaced by newer drugs such as semaglutide and tirzepatide.
The Cost Factor
Gross Medicare Part D spending on GLP-1 medications rose approximately fivefold between 2019 and 2024. However, rebates negotiated by pharmacy benefit managers (PBMs) significantly reduce the net cost. While gross spending reached $27.5 billion in 2024, net spending, after rebates, is estimated to be closer to $14 billion. Semaglutide-based drugs account for over half of total spending.
Policy Shifts and Future Access
The Centers for Medicare & Medicaid Services (CMS) is addressing coverage gaps through the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) pilot program. This initiative, starting with Medicaid in 2026 and potentially expanding to Medicare in 2027, aims to negotiate pricing, test expanded coverage approaches, and integrate lifestyle interventions with medication access. Participation is voluntary for manufacturers and health plans.
Medicare’s drug price negotiation program will introduce lower negotiated prices for certain GLP-1 medications, with semaglutide negotiations expected in 2027 and dulaglutide in 2028.
The Rise of Oral Formulations
The introduction of oral GLP-1 formulations could further increase utilization, as pills are often preferred by patients over injections.
What Does This Mean For The Future
GLP-1 supplements are being advertised as more affordable alternatives to blockbuster weight-loss drugs. Here’s what doctors suppose about them. https://t.co/4PT1p0FQwk
— TODAY (@TODAYshow) September 20, 2024
The convergence of strong clinical evidence, rising patient demand, federal pressure to reduce drug prices, and potential coverage expansion suggests a continued trajectory of growth for GLP-1 medications. The future likely involves balancing broader patient access with sustainable healthcare spending through negotiated pricing and integrated care models.
Did you recognize? The increasing demand for GLP-1s has led to supply chain challenges and, in some cases, shortages of certain medications.
Frequently Asked Questions
What are GLP-1 medications?
GLP-1 medications are a class of drugs originally designed to treat type 2 diabetes. They work by mimicking a natural hormone that helps regulate blood sugar and can also promote weight loss.
Does Medicare cover GLP-1s for weight loss?
Currently, Medicare generally does not cover GLP-1 medications specifically for weight loss. Coverage is typically limited to conditions like type 2 diabetes and cardiovascular disease.
What is the BALANCE program?
BALANCE is a CMS pilot program aimed at testing expanded coverage approaches for GLP-1 medications, integrating them with lifestyle interventions, and negotiating pricing structures.
Pro Tip: Talk to your healthcare provider to determine if a GLP-1 medication is appropriate for your individual health needs and to discuss coverage options.
Have questions about GLP-1s and Medicare? Share your thoughts in the comments below!
